La sagacidad que te permitirá improvisar el brindis de gala en la boda de tu nieta no estará en la farmacia, al menos, en un futuro cercano. Cada decisión que tomas hoy, desde qué comes, hasta cómo duermes o cuánto te mueves, ya está o bien protegiendo, o bien atacando tu cerebro.
Aquí dejo el audio del capítulo y abajo las referencias.
Referencias (por orden de aparición):
BIBLIOGRAFÍA RECOMENDADA: Bredesen, D. (2021). The First Survivors of Alzheimer’s: How Patients Recovered Life and Hope in Their Own Words. Disponible en Amazon.
Rao, R. V., Kumar, S., Gregory, J., Coward, C., Okada, S., Lipa, W., Kelly, L., & Bredesen, D. E. (2021). ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline. Biomedicines, 9(10), 1348. https://doi.org/10.3390/biomedicines9101348
Hart, B. (2022). Have Scientists Been Wrong About Alzheimer’s for Decades? Intelligencer. https://nymag.com/intelligencer/2022/08/have-scientists-been-wrong-about-alzheimers-for-decades.html
Piller, C. (2022). Potential fabrication in research images threatens key theory of Alzheimer’s disease. (2022). Science. Vol 377, Issue 6604. https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006). A specific amyloid-β protein assembly in the brain impairs memory. Nature, 440(7082), 352-357. https://doi.org/10.1038/nature04533
Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R, … & Halliday, G. M. (2017). Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 9, 10-20. https://doi.org/10.1016/j.dadm.2017.05.005
Medeiros, R., Baglietto-Vargas, D., & LaFerla, F. M. (2011). The role of tau in Alzheimer’s disease and related disorders. CNS Neuroscience & Therapeutics, 17(5), 514-524. https://doi.org/10.1111/j.1755-5949.2010.00177.x
Riederer, P., Berg, D., Casadei, N., Cheng, F., Classen, J., … & Monoranu, C. (2019). α-Synuclein in Parkinson’s disease: Causal or bystander? Journal of Neural Transmission, 126(7), 815-840. https://doi.org/10.1007/s00702-019-02025-9
Guo, L., Salt, T. E., Luong, V., Wood, N., Cheung, W., … & Cordeiro, M. F. (2007). Targeting amyloid-beta in glaucoma treatment. Proceedings of the National Academy of Sciences of the United States of America, 104(33), 13444-13449. https://doi.org/10.1073/pnas.0703707104
Chiasseu, M., Cueva Vargas, J. L., Destroismaisons, L., Vande Velde, C., Leclerc, N., & Di Polo, A. (2016). Tau Accumulation, Altered Phosphorylation, and Missorting Promote Neurodegeneration in Glaucoma. The Journal of Neuroscience, 36(21), 5785-5798. https://doi.org/10.1523/JNEUROSCI.3986-15.2016
Bredesen D. E. (2014). Reversal of cognitive decline: a novel therapeutic program. Aging, 6(9), 707–717. https://doi.org/10.18632/aging.100690
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., … Kivipelto, M. (2015). A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. The Lancet, 385(9984), 2255-2263. https://doi.org/10.1016/S0140-6736(15)60461-5
